
miR-548-3p/DAG1 axis promotes the development of laryngeal carcinoma 217
Vol. 63(3): 206 - 217, 2022
8. Liang T, Guo L, Liu C. Genome-wide analy-
sis of mir-548 gene family reveals evolutio-
nary and functional implications. J Biomed
Biotechnol 2012;2012:679563.
9. Luo Z, Li D, Luo X, Li L, Gu S, Yu L, Yuan-
zheng Ma. Decreased expression of miR-
548c-3p in osteosarcoma contributes to cell
proliferation via targeting ITGAV. Cancer
Biother Radiopharm 2016;31(5):153-158.
10. Rehbein G, Schmidt B, Fleischhacker M.
Extracellular microRNAs in bronchoalveo-
lar lavage samples from patients with lung
diseases as predictors for lung cancer. Clin
Chim Acta 2015;450:78-82.
11. Lorrai R, Gandolfi F, Boccaccini A, Ruta V,
Possenti M, Tramontano A, Costantino P,
Lepore R, Vittorioso P. Genome-wide RNA-
seq analysis indicates that the DAG1 trans-
cription factor promotes hypocotyl elon-
gation acting on ABA, ethylene and auxin
signaling. Sci Rep 2018;8(1):15895.
12. Ju Y, Wu X, Wang H, Li B, Long Q, Zhang
D, Chen H, Xiao N, Li F, Zhang S, Yang S.
Genomic landscape of head and neck squa-
mous cell carcinoma across different ana-
tomic sites in Chinese population. Front
Genet 2021;12:680699.
13. He G, Pang R, Han J, Jia J, Ding Z, Bi
W, Yu J, Chen L, Zhang J, Sun Y. TIN-
CR inhibits the proliferation and invasion
of laryngeal squamous cell carcinoma by
regulating miR-210/BTG2. BMC Cancer
2021;21(1):753.
14. Chen Z, Zhang C, Chen J, Wang D, Tu J,
Van Waes C, Saba NF, Chen ZG, Chen Z.
The proteomic landscape of growth factor
signaling networks associated with FAT1
mutations in head and neck cancers. Can-
cer Res 2021;81(17):4402-4416.
15. Bahig H, Lapointe A, Bedwani S, de Gui-
se J, Lambert L, Filion E, Roberge D,
Létourneau-Guillon L, Blais D, Ng SP,
Nguyen-Tan PF. Dual-energy computed to-
mography for prediction of loco-regional
recurrence after radiotherapy in larynx and
hypopharynx squamous cell carcinoma. Eur
J Radiol 2019;110:1-6.
16. Hughes RT, Beuerlein WJ, O’Neill SS, Po-
rosnicu M, Lycan TW, Waltonen JD, Friz-
zell BA, Greven KM. Human papillomavi-
rus-associated squamous cell carcinoma
of the larynx or hypopharynx: Clinical
outcomes and implications for laryngeal
preservation. Oral Oncol 2019;98:20-27.
17. Garajei A, Parvin M, Mohammadi H, Alla-
meh A, Hamidavi A, Sadeghi M, Emami
A, Brand S. Evaluation of the expression of
miR-486-3p, miR-548-3p, miR-561-5p and
miR-509-5p in tumor biopsies of patients
with oral squamous cell carcinoma. Patho-
gens 2022;11(2):211.
18. Perez-Ordoñez B. Neuroendocrine carcino-
mas of the larynx and head and neck: cha-
llenges in classification and grading. Head
Neck Pathol 2018;12(1):1-8.
19. Reinhard JR, Lin S, McKee KK, Meinen
S, Crosson SC, Sury M, Hobbs S, Maier
G, Yurchenco PD, Rüegg MA. Linker pro-
teins restore basement membrane and co-
rrect LAMA2-related muscular dystrophy in
mice. Sci Transl Med 2017;9(396).
20. Leibovitz Z, Mandel H, Falik-Zaccai TC,
Ben Harouch S, Savitzki D, Krajden-
Haratz K, Gindes L, Tamarkin M, Lev
D, Dobyns WB, Lerman-Sagie T. Walker-
Warburg syndrome and tectocerebellar
dysraphia: A novel association caused by
a homozygous DAG1 mutation. Eur J Pae-
diatr Neurol 2018;22(3):525-531.
21. Harris E, McEntagart M, Topf A, Lochmü-
ller H, Bushby K, Sewry C, Straub V. Cli-
nical and neuroimaging findings in two
brothers with limb girdle muscular dystro-
phy due to LAMA2 mutations. Neuromuscul
Disord 2017;27(2):170-174.
22. Sarkozy A, Foley AR, Zambon AA, Bönne-
mann CG, Muntoni F. LAMA2-related dys-
trophies: clinical phenotypes, disease bio-
markers, and clinical trial readiness. Front
Mol Neurosci 2020;13:123.
23. Zhou S, Ouyang W, Zhang X, Liao L, Pi X,
Yang R, Mei B, Xu H, Xiang S, Li J. UTRN
inhibits melanoma growth by suppressing
p38 and JNK/c-Jun signaling pathways.
Cancer Cell Int 2021;21(1):88.
24. Wood CL, Suchacki KJ, van ‘t Hof R,
Cawthorn WP, Dillon S, Straub V, Wong
SC, Ahmed SF, Farquharson C. A compa-
rison of the bone and growth phenotype of
mdx, mdx:Cmah(-/-) and mdx:Utrn (+/-)
murine models with the C57BL/10 wild-
type mouse. Dis Model Mech 2020;13(2).